Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > FDA taking a year for IBRX review
View:
Post by N0taP00p on Nov 11, 2022 10:59am

FDA taking a year for IBRX review

Doesn't Immunity Bio have BTD already? If their biologics application can take almost a year to get approved, why would Theralase's go any faster? I know there's no BCG involved and fewer treatments. But still, wondering. Health Canada is not even on the radar.
Comment by ScienceFirst on Nov 11, 2022 1:07pm
I documented the differences recently.
Comment by Rumpl3StiltSkin on Nov 11, 2022 1:17pm
Yep, Since this Phase 2 is Pivotal, TLT should have Accelerated Approval in mid 2023.
Comment by FGPstock on Nov 11, 2022 1:21pm
Ben, i guess our definition of "receive" is differnt. in my world, "receive" means TLT gets or is granted BTD. I guess you difine receive as "apply". Not sure why you mention meeting with fda aug/sep 2022, they way i read it is that is when TLT applies for BTD, its so obvious, .lol... ScienceFirst (7725) User Actions   May 31, 2022 - 03:36 PM 135 Reads ...more  
Comment by ScienceFirst on Nov 11, 2022 3:08pm
FGPStock ... If you had taken the time to look at the Feb. 2022 corporate presentation (which obviously you didn't considering your questioning about the pp), you would have understood in a wink where do the Breakthrough designation application could start.  It's all there for you. But instead of consulting it, and because you had a hard time understanding where it would fit on the ...more  
Comment by FGPstock on Nov 11, 2022 3:24pm
do you know the definaition of "receive"? RE:When push comes to shove... Eoganacht ... Everything matches with the updated corporate presentation of Feb. 7 where they expect to receive a Breakthrough designation around November/December.
Comment by ScienceFirst on Nov 11, 2022 4:28pm
Do you know the definition of "definaition" If you had consulted the corporate presentation instead of being insecure and start discussions on why a po ... ____________   FGPstock - (11/11/2022 3:24:58 PM) RE:RE:RE:RE:FDA taking a year for IBRX review do you know the definaition of "receive"?
Comment by ScienceFirst on Nov 11, 2022 4:32pm
 Do you know the definition of "definaition" If you had consulted the corporate presentation instead of being insecure and start discussions on why a pp ... ____________   FGPstock - (11/11/2022 3:24:58 PM) RE:RE:RE:RE:FDA taking a year for IBRX review do you know the definaition of "receive"?
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250